CL Shapiro, A Recht - The New England journal of medicine, 2001 - nejm.highwire.org Women with primary invasive breast cancer receive both local and systemic
treatment. Surgery and radiation therapy are local treatments given to reduce
the risk of recurrent cancer in the breast, chest wall, and regional lymph ... Cited by 186 - Related articles - BL Direct - All 7 versions
- ►lsh.is [PDF] HJ Burstein, EP Winer - The New England journal of medicine, 2000 - nejm.highwire.org There are more than 2 million women in the United States alone who are living
with a history of breast cancer. 1 , 2 Screening programs have increased the
number of women in whom invasive or noninvasive breast cancer has been ... Cited by 142 - Related articles - BL Direct - All 9 versions
- ►ucsf.edu [PDF] VC Jordan - J. Med. Chem, 2003 - pubs.acs.org The critical step in the development of novel approaches to prevent disease is
the translation of laboratory concepts to clinically useful interventions. The
expanding database for selective estrogen receptor modulators (SERMs) ... Cited by 140 - Related articles - BL Direct - All 10 versions
- ►jcojournal.org B Gerber, A Krause, H Muller, T Reimer, T Kulz … - Journal of Clinical Oncology, 2000 - jcojournal.org Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
From the Department of Obstetrics and Gynecology, Department of Pathology, ... Cited by 108 - Related articles - BL Direct - All 11 versions
I Cohen - Gynecologic Oncology, 2004 - Elsevier Results. Endometrial polyps represent the most common endometrial pathology
associated with postmenopausal tamoxifen exposure. A high rate of malignancy was
reported in these polyps. Endometrial hyperplasia, endometrial polyps, ... Cited by 67 - Related articles - All 3 versions
RT Chlebowski - N Engl J Med, 2000 - views.vcu.edu CHEMOPREVENTION Tamoxifen and Risk Reduction The risk of breast cancer is
related to levels of en- dogenous1,2 and exogenous3-5 hormones. Tamoxifen and
raloxifene, which are selective estrogen-receptor modulators, can be used ... Cited by 55 - Related articles - View as HTML - All 6 versions
BK Dunn, LG Ford - Breast Journal, 2001 - interscience.wiley.com Abstract: The continued widespread prevalence of breast cancer supports placing
a high priority on research aimed at its primary prevention, particularly among
women who are at increased risk for developing this disease. The suggestion ... Cited by 47 - Related articles - All 3 versions
SR Goldstein - Ann NY Acad Sci, 2001 - interscience.wiley.com Abstract: Tamoxifen, the first clinically available SERM, was developed in 1966
and approved by the FDA (United States Food and Drug Administration) in 1978. It
is the most prescribed antineoplastic drug in the world, with approximately ... Cited by 33 - Related articles - All 3 versions
MFK Fung, A Reid, W Faught, T Le, C Chenier … - Gynecologic Oncology, 2003 - Elsevier Over a 6-year period, 304 women on tamoxifen as adjuvant therapy for breast
cancer were recruited into the current study. Standard demographic data as well
as duration of tamoxifen use were collected. Patients were assessed at ... Cited by 30 - Related articles - All 3 versions
N Wolmark, BK Dunn - Annals of the New York Academy of Sciences, 2001 - ncbi.nlm.nih.gov The Breast Cancer Prevention Trial (P-1: BCPT) of the National Surgical Adjuvant
Breast and Bowel Project (NSABP) randomized 13,388 women, > or = 35 years of
age, at increased risk for breast cancer [> or = 1.66% by Gail model ... Cited by 27 - Related articles - All 2 versions
